Farxiga, a constituent of a drug class called as SGLT-2 inhibitors (sodium-glucose co-transporter 2) has been given a nod by FDA to fulfill another function, and that is reducing heart failure risks for people with type 2 diabetes.
The news was welcomed in all quarters as according to AstraZeneca’s Ruud Dobber, people with type 2 diabetes were at highest risk to heart failure than stroke or heart attack. Approving the drug usage for lowering heart failure risk would prove a boon to the large number of Americans with type 2 diabetes.
The nod for its new usage was given by FDA after examining the outcomes of a study titled DECLARE-TIMI 58 CV Outcomes trial. The trial involved an examination of 17,000 plus type 2 diabetes afflicted patients also having or more open to risk of heart disease. The participants were given the placebo or the medication on a random basis. They were evaluated for a period of 4 years and more. The heart attack rates or fatalities witnessed no differences between the two groups. However, patients who received medication had 27% less chances of facing hospitalization for heart failure.
Farxiga works by triggering the kidneys to transport the sugar out from the body through urine and thus reducing blood sugar. Though the reduction in hospitalization rates was not a significant figure it was a benefit in every sense and this secondary usage made it a popularly prescribed drug. However, it is essential to be aware of the risks or side effects too. As far as Farxiga was concerned it comprised kidney injury, drop in blood pressure, reduced blood sugar besides other health issues.
Supply of the drug for a 30 day period would entail a list price of $492.41 as per the website of the company. Usage of coupons, assistance programs, health insurance etc. would help to lower the costs.